Brokerages expect Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) to post earnings per share of ($ 0.04) for the current fiscal quarter, reports Zacks Investment Research. No analyst has made any estimates on Diffusion Pharmaceuticals’ earnings. Diffusion Pharmaceuticals reported earnings of ($ 0.06) per share for the same quarter last year, suggesting a positive year-over-year growth rate of 33.3%. The company is expected to release its next results on Wednesday March 16.
According to Zacks, analysts expect Diffusion Pharmaceuticals to report annual earnings of ($ 0.22) per share for the current year, with EPS estimates ranging from $ 0.26 to $ 0.17. For the next fiscal year, analysts expect the company to post earnings of ($ 0.17) per share, with EPS estimates ranging from $ 0.17 to $ 0.16. Zacks Investment Research earnings per share averages are an average based on a survey of research analysts who cover Diffusion Pharmaceuticals.
Diffusion Pharmaceuticals (NASDAQ: DFFN) last released its quarterly results on Wednesday, November 10. The company reported ($ 0.12) EPS for the quarter, missing analyst consensus estimates of ($ 0.04) by ($ 0.08).
Several hedge funds and other institutional investors have recently changed their holdings in the company. Geode Capital Management LLC increased its stake in Diffusion Pharmaceuticals shares by 6.7% during the third quarter. Geode Capital Management LLC now owns 858,408 shares of the company valued at $ 437,000 after purchasing an additional 54,118 shares in the last quarter. Virtu Financial LLC increased its stake in Diffusion Pharmaceuticals shares by 86.1% during the second quarter. Virtu Financial LLC now owns 285,621 shares of the company valued at $ 209,000 after purchasing an additional 132,157 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Diffusion Pharmaceuticals during the second quarter valued at approximately $ 110,000. Millennium Management LLC acquired a new position in Diffusion Pharmaceuticals during the first quarter valued at approximately $ 307,000. Finally, State Street Corp purchased a new position in Diffusion Pharmaceuticals during the second quarter valued at approximately $ 336,000. Hedge funds and other institutional investors hold 9.79% of the company’s shares.
NASDAQ: DFFN opened at $ 0.38 on Monday. The stock has a market cap of $ 38.84 million, a price-to-earnings ratio of -1.36 and a beta of 1.49. The company has a fifty-day simple moving average of $ 0.43 and a two hundred-day simple moving average of $ 0.55. Diffusion Pharmaceuticals has a 12-month low of $ 0.34 and a 12-month high of $ 1.85.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals, Inc. is a clinical stage company engaged in the development of treatments for life-threatening conditions. It offers trans sodium crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, Virginia.
Recommended story: How are outstanding shares different from authorized shares?
Get a Free Copy of Zacks’ Research Report on Diffusion Pharmaceuticals (DFFN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Diffusion Pharmaceuticals now?
Before you consider Diffusion Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold … and Diffusion Pharmaceuticals was not on the list.
While Diffusion Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here